Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation

Ann Hematol. 2003 May;82(5):295-8. doi: 10.1007/s00277-003-0621-5. Epub 2003 Mar 29.

Abstract

We report on a 35-year-old woman who underwent allogeneic stem cell transplantation (SCT) in second complete remission (CR) of acute myeloid leukemia (AML) after reduced-intensity conditioning with fludarabine and 2 Gy of total body irradiation. For graft-versus-host disease (GVHD) prophylaxis, cyclosporin A (CsA) and mycophenolate mofetil (MMF) were given. On day 27 after SCT complete hematological remission and donor chimerism was documented. However, in CD34(+) bone marrow cells 28% of recipient hematopoiesis persisted. On day +59 leukemic relapse occurred. After discontinuation of CsA and onset of GVHD, complete donor chimerism and hematological CR were achieved which has been maintained for 14 months.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adult
  • Combined Modality Therapy
  • Female
  • Graft vs Host Disease / prevention & control
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy*
  • Leukemia, Myeloid / therapy*
  • Recurrence
  • Remission Induction
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous

Substances

  • Immunosuppressive Agents